United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - alitretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - alitretinoin - oral capsule - 30mg

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis australia pty ltd - acitretin -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - acitretin -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - acitretin -

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - acitretin, quantity: 25 mg - capsule, hard - excipient ingredients: gelatin; iron oxide black; iron oxide red; sodium ascorbate; microcrystalline cellulose; iron oxide yellow; spray-dried liquid glucose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of severe intractable psoriasis in all its forms. severe forms of disorders of keratinisation such as: hyperkeratosis palmaris et plantaris; pustulosis palmaris et plantaris; ichthyosis; keratosis follicularis (darier's disease); lichen planus affecting the skin or the mucosae; pityriasis rubra pilaris.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - acitretin, quantity: 10 mg - capsule, hard - excipient ingredients: iron oxide red; spray-dried liquid glucose; iron oxide yellow; iron oxide black; gelatin; microcrystalline cellulose; sodium ascorbate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of severe intractable psoriasis in all its forms. severe forms of disorders of keratinisation such as: hyperkeratosis palmaris et plantaris; pustulosis palmaris et plantaris; ichthyosis; keratosis follicularis (darier's disease); lichen planus affecting the skin or the mucosae; pityriasis rubra pilaris.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin capsules, usp are indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, acitretin capsules, usp should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, acitretin capsules, usp should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — acitretin capsules, usp can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. pregnancy category x:  ( see boxed contraindications and warnings. ) acitretin is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed warnings: hepatotoxicity, warnings: lipids and possible cardiovascular effects, and precautions). an increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. consequently, the combination of methotrexate with acitretin is also contraindicated (see precautions: drug interactions). since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see warnings: pseudotumor cerebri). acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids .

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin capsules, usp are indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, acitretin capsules, usp should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, acitretin capsules, usp should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — acitretin capsules, usp can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. pregnancy category x:  ( see boxed contraindications and warnings. ) acitretin is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed warnings: hepatotoxicity, warnings: lipids and possible cardiovascular effects, and precautions). an increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. consequently, the combination of methotrexate with acitretin is also contraindicated (see precautions: drug interactions). since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see warnings: pseudotumor cerebri). acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids .

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin capsules, usp are indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, acitretin capsules, usp should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, acitretin capsules, usp should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — acitretin capsules, usp can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. pregnancy category x:  ( see boxed contraindications and warnings. ) acitretin is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed warnings: hepatotoxicity, warnings: lipids and possible cardiovascular effects, and precautions). an increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. consequently, the combination of methotrexate with acitretin is also contraindicated (see precautions: drug interactions). since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see warnings: pseudotumor cerebri). acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids .